Acute Ischemic Stroke Therapeutics Market Size to grow by USD 1524.49 million between 2023-2027
According to a research report “ Acute Ischemic Stroke Therapeutics Market” by Type (Thrombolytics, Anticoagulants, Antiplatelets, Antihypertensives) Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2027 published by Technavio, the market size is estimated to grow by USD 1524.49 million, at a CAGR of 5.72% during the forecast period. Ischemic stroke, which accounts for approximately 87% of all stroke cases according to the Centers for Disease Control and Prevention (CDC), is a major public health concern and a leading cause of disability and death worldwide. Acute Ischemic Stroke (AIS) is the most common form of stroke, occurring when the blood supply to a portion of the brain is obstructed by plaque or a blood clot. The consequences of untreated AIS can range from disability to death. To mitigate these risks, timely administration of thrombolytic agents such as alteplase within the therapeutic window of three to four and a half hours after the onset of the first symptom is recommended. This intervention can help restore blood flow to the affected brain region and minimize the potential for long-term disability or fatality..
Browse market data tables, figures, and in-depth TOC on “Acute Ischemic Stroke Therapeutics Market” by Type (Thrombolytics, Anticoagulants, Antiplatelets, Antihypertensives) Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2027. Download Free Sample
By Type, the Thrombolytics segment is projected to dominate the market size in 2024
In the acute ischemic stroke market, thrombolytic agents play a pivotal role as they are utilized for the process of thrombolysis, which involves the breaking down of blood clots, or thrombi, in blood vessels. Activase, a dominant thrombolytic drug, is approved by the US Food and Drug Administration (FDA) for intravenous administration at a dose of 0.9 mg per kg body weight, infused over an hour, with 10% of the total dose administered as an initial bolus within one minute. This therapeutic intervention aims to restore blood flow and minimize the potential neurological damage caused by the stroke.
By Distribution Channel, Hospital pharmacies segment is expected to hold the largest market size for the year 2024
In the Acute Ischemic Stroke Therapeutics Market, hospital pharmacies represent a significant distribution channel for pharmaceuticals. These pharmacies procure medications directly from pharmaceutical companies for use in treating both outpatients and inpatients within hospitals. The drugs stocked in hospital pharmacies cater to various therapeutic areas, including cardiology, neurology, urology, and pathogenic infections. Hospital pharmacies serve a crucial role in acquiring, storing, and selling medications to hospital patients during their treatment tenure. As of 2022, this segment holds the largest market share and is expected to maintain its dominance throughout the forecast period. The increasing preference for compounded drugs in healthcare has further boosted the significance of hospital pharmacies in this market.
North America is forecasted to hold the largest market size by region in 2024
The acute ischemic stroke (AIS) therapeutics market in North America is poised for significant growth due to the high incidence of strokes in the region. According to the Centers for Disease Control and Prevention (CDC) and the Government of Canada, approximately 1.2 million people in North America experience a stroke annually, with around 15-20% resulting in fatalities. This high prevalence can be attributed to the prevalence of risk factors such as aging population, obesity, hypertension, and diabetes. The region's market growth is further bolstered by a robust late-stage pipeline of potential treatments.
The Acute Ischemic Stroke Therapeutics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
The Acute Ischemic Stroke Therapeutics Market encompasses a range of treatments for stroke caused by the blockage of blood vessels due to atherosclerosis plaques. The market includes products administered through both parenteral and oral routes. The distribution channel for these therapies spans from hospital pharmacies to retail pharmacies. Key therapeutic classes include antihypertensives, statins, anticoagulants, and antiplatelets. Antihypertensives help manage high blood pressure, a significant risk factor for stroke. Statins reduce cholesterol levels to prevent plaque buildup. Anticoagulants and antiplatelets prevent blood clots from forming or growing larger. Thrombolytics, such as tenecteplase and alteplase, are crucial in acute treatment. They work by activating the clot-dissolving protein, Tissue Plasminogen Activator (tPA), to break down blood clots. Other advanced treatments include endovascular mechanical thrombectomy, angioplasty, carotid endarterectomy, and various diagnostic tools like echocardiography, electrocardiography, cerebral angiography, carotid ultrasound, magnetic resonance imaging, and computed tomography. Treatment options also include antihypertensive medications, antiplatelets (aspirin, clopidogrel), anticoagulants (warfarin, heparin), thrombolytics (tenecteplase, alteplase), and other drug classes. The choice of treatment depends on the severity and location of the stroke, as well as the patient's overall health condition.
Market Research Overview
The Acute Ischemic Stroke Therapeutics Market encompasses various drug classes and routes of administration, including parenteral and oral forms, sold through online pharmacies, retail pharmacies, and hospital pharmacies. Key drug classes include antihypertensives, statins, anticoagulants, and antiplatelets, with thrombolytics such as tenecteplase and alteplase being the primary focus. The Defense Health Agency plays a crucial role in the distribution of these life-saving medications. Neuroimaging technologies, including MRI scans, CT scans, and neuroimaging techniques, are essential in diagnosing acute ischemic stroke. Risk factors such as obesity, diabetes, and high blood pressure, along with the aging population, contribute to the growing prevalence of this condition. Brain cell damage and disrupted blood flow result from blood clots formed in the arteries and blood vessels, often due to atherosclerosis plaques. Clot dissolving drugs like thrombolytics are administered intravenously to restore blood flow to the brain. Other treatments include mechanical thrombectomy, angioplasty, carotid endarterectomy, and various diagnostic procedures such as echocardiography, electrocardiography, cerebral angiography, and carotid ultrasound. The market for these therapeutics continues to grow due to the increasing incidence of acute ischemic stroke and the development of new treatments and technologies.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
